Você está no menu de acessibilidade

Utilize este identificador para citar ou criar um link para este item: http://acervodigital.unesp.br/handle/11449/117725
Título: 
Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy
Autor(es): 
Instituição: 
  • Hosp Ninos Dr Ricardo Gutierrez
  • Inst Diagnost & Referencia Epidemiol
  • Universidade Estadual Paulista (UNESP)
  • Univ Nacl Autonoma Mexico
ISSN: 
1007-9327
Financiador: 
  • project Salud
  • CONACYT
  • PAPIIT
  • Direccion General de Asuntos del Personal Academico, Universidad Nacional Autonoma de Mexico
  • Argentine National Agency for Scientific and Technology Promotion (PICT)
  • National Research Council (CONICET, PIP)
Número do financiamento: 
  • project Salud2012-C01-181585
  • PAPIITTA200112
  • Argentine National Agency for Scientific and Technology Promotion (PICT)804
  • National Research Council (CONICET, PIP)51
Resumo: 
Hepatitis C virus (HCV) infection represents an important public health problem worldwide. Reduction of HCV morbidity and mortality is a current challenge owned to several viral and host factors. Virus molecular evolution plays an important role in HCV transmission, disease progression and therapy outcome. The high degree of genetic heterogeneity characteristic of HCV is a key element for the rapid adaptation of the intrahost viral population to different selection pressures (e.g., host immune responses and antiviral therapy). HCV molecular evolution is shaped by different mechanisms including a high mutation rate, genetic bottlenecks, genetic drift, recombination, temporal variations and compartmentalization. These evolutionary processes constantly rearrange the composition of the HCV intrahost population in a staging manner. Remarkable advances in the understanding of the molecular mechanism controlling HCV replication have facilitated the development of a plethora of direct-acting antiviral agents against HCV. As a result, superior sustained viral responses have been attained. The rapidly evolving field of anti-HCV therapy is expected to broad its landscape even further with newer, more potent antivirals, bringing us one step closer to the interferon-free era. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
Data de publicação: 
21-Nov-2014
Citação: 
World Journal Of Gastroenterology. Pleasanton: Baishideng Publishing Group Inc, v. 20, n. 43, p. 15992-16013, 2014.
Duração: 
15992-16013
Publicador: 
Baishideng Publishing Group Inc
Palavras-chaves: 
  • Hepatitis C virus
  • Evolution
  • Phylogenetics
  • Drug resistance
  • Clinical outcome
Fonte: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239486/
Endereço permanente: 
Direitos de acesso: 
Acesso restrito
Tipo: 
outro
Fonte completa:
http://repositorio.unesp.br/handle/11449/117725
Aparece nas coleções:Artigos, TCCs, Teses e Dissertações da Unesp

Não há nenhum arquivo associado com este item.
 

Itens do Acervo digital da UNESP são protegidos por direitos autorais reservados a menos que seja expresso o contrário.